Bernstein lowers Coloplast stock price target to DKK760 on conservative margin outlook

Published 11/09/2025, 13:16
Bernstein lowers Coloplast stock price target to DKK760 on conservative margin outlook

Investing.com - Bernstein SocGen Group lowered its price target on Coloplast A/S (CSE:COLOB) to DKK760.00 from DKK790.00 on Thursday, while maintaining an Outperform rating on the stock. The healthcare equipment giant, with a market capitalization of $22 billion, currently trades at 34.5 times earnings, according to InvestingPro data.

The price target adjustment follows Coloplast’s Capital Markets Day held on September 2, where the company issued five-year guidance extending to fiscal year 2029/30. Bernstein noted that the company’s guidance implies minimal to no margin expansion at the group level.

The research firm highlighted an apparent disconnect in the guidance, as each of Coloplast’s divisional presentations during the Capital Markets Day indicated margin uplift, contrasting with the flat overall margin guidance.

Bernstein described the current investment case as "unusually murky" but suggested this creates "an attractive and rare opportunity" for investors to build a position in the stock.

The firm pointed out that Coloplast is trading at 24 times one-year forward price-to-earnings ratio, representing a significant discount to its three-year average of 34 times, making the stock "cheap for a high quality asset."

In other recent news, Coloplast has seen mixed analyst opinions regarding its stock price target. Deutsche Bank has lowered its price target for Coloplast to DKK660.00, maintaining a Hold rating. This decision follows the company’s Capital Markets Day, where Coloplast discussed its organic sales growth targets through 2030. On the other hand, RBC Capital has increased its price target for Coloplast to DKK710.00, keeping a Sector Perform rating. RBC’s adjustment comes in anticipation of Coloplast’s upcoming Capital Markets Day, where they expect the company to outline its mid-term financial expectations with an emphasis on innovation. These developments indicate differing analyst perspectives on Coloplast’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.